MREO News and Press, Mereo BioPharma Group From 03/26/24

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Mereo BioPharma Group plc (MREO) is expected to report for Q4 2023

2024-03-14 17:34:14 ET Summary Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development...

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...

2024-01-16 09:45:09 ET Microsoft Corporation (MSFT) MSFT is trading UP for the last 5 days, and it at trading at $392.38 with volume of 9,037,995 and a one day change of $3.91 (1.01%). Microsoft Corporation has a 52-week low of 230.68 and a 52-week high of $390.68. The business's 50...

2024-01-08 08:40:02 ET More on Mereo BioPharma Group Mereo BioPharma: Lagging Stock Despite Positive Data Seeking Alpha’s Quant Rating on Mereo BioPharma Group For further details see: Mereo BioPharma provides update on pipeline progress, reaffirms cash ru...

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on de...

2023-12-13 04:50:52 ET Summary Mereo BioPharma has shifted its focus from developing anti-TIGIT molecules to rare disease programs. The company's current pipeline includes programs for Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, and anti-TIGIT ...

2023-11-14 21:51:36 ET Summary Ultragenyx shows clinical innovation in rare diseases; financial growth is offset by high net loss and cash burn. Recent earnings indicate YOY revenue growth but a substantial net loss; operating expenses have decreased. Ultragenyx's liquid asset...

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial ...